What is Mycophenolate Mofetil Used For?
Mycophenolate mofetil (MMF) is FDA-approved for preventing organ rejection in patients receiving kidney, heart, or liver transplants (including pediatric patients ≥3 months old), and is also used off-label as a steroid-sparing immunosuppressant in autoimmune hepatitis and as maintenance therapy for lupus nephritis. 1, 2, 3
FDA-Approved Indications
The primary FDA-approved use is prophylaxis of organ rejection in allogeneic transplant recipients 1:
- Renal transplantation (adults and pediatrics)
- Cardiac transplantation (adults and pediatrics ≥3 months)
- Hepatic transplantation (adults and pediatrics ≥3 months)
MMF must be used concomitantly with cyclosporine and corticosteroids in these settings 1. The standard adult dosing is 1-1.5 g twice daily, while pediatric dosing is 600 mg/m² twice daily (up to maximum 1 g twice daily for renal transplant, or 900 mg/m² twice daily for cardiac/hepatic transplant) 1, 4.
Guideline-Supported Off-Label Uses
Lupus Nephritis
MMF is the recommended first-line maintenance therapy after initial treatment of proliferative lupus nephritis 3. The KDIGO 2024 guidelines provide specific dosing:
- Early maintenance phase: 750-1000 mg twice daily
- Continue until complete response is achieved, then taper
- Total duration of immunosuppression (initial + maintenance) should be ≥36 months 3
MMF is preferred over azathioprine for maintenance therapy due to superior efficacy in preventing renal flares 3. Azathioprine serves as an alternative only for patients who cannot tolerate MMF, lack access to it, or are considering pregnancy 3.
Autoimmune Hepatitis
MMF is recommended as second-line therapy for autoimmune hepatitis in patients who are intolerant to or fail standard treatment with azathioprine 2. The 2025 EASL guidelines specify:
- Dosing: Start at 1,000 mg/day, increase to 1,500-2,000 mg/day at week 2
- Used in combination with predniso(lo)ne (starting at 0.5 mg/kg/day)
- MMF can be initiated simultaneously with corticosteroids (unlike azathioprine, which starts 2 weeks later)
- MMF-related toxicity is rare, allowing for less frequent early monitoring compared to azathioprine 2
The guidelines note that MMF is particularly valuable when azathioprine causes adverse effects (which occur most frequently in the first 6 weeks) 2.
Other Documented Uses
While not guideline-endorsed, MMF has been used in various autoimmune and immune-mediated conditions 5, 6:
- Systemic lupus erythematosus (non-renal manifestations)
- Pemphigus vulgaris
- Myasthenia gravis
- Polymyositis
- Systemic sclerosis (interstitial lung disease and skin fibrosis)
- Autoimmune/immune-mediated CNS diseases in pediatrics 7
However, these indications lack the robust guideline support and should be considered only when standard therapies have failed.
Critical Safety Considerations
MMF is highly teratogenic and absolutely contraindicated in pregnancy 1. Key precautions include:
- Females of reproductive potential must use two forms of contraception simultaneously
- Pregnancy testing required before initiation
- Healthcare providers must report any pregnancy exposure to the Mycophenolate Pregnancy Registry (1-800-617-8191)
- Postmarketing data show 45% spontaneous abortion rate and 22% malformation rate in exposed pregnancies 1
- Similar contraceptive precautions are advisable for males 2
Common adverse effects include gastrointestinal intolerance (29%) and infections (23%), with discontinuation rates of approximately 16% due to side effects 8.
Dosing Adjustments
- Renal impairment: Dose reduction may be necessary as patients with CKD are more susceptible to MPA adverse effects 3
- Therapeutic drug monitoring: While not routinely recommended, measuring MPA exposure may help in patients with unsatisfactory response or increased toxicity risk 3
- Elderly patients: May be at increased risk of adverse reactions; dose selection should be cautious 1